| Protein kinase CK2 in health and disease: CK2: a key player in cancer biology JH Trembley, G Wang, G Unger, J Slaton, K Ahmed Cellular and molecular life sciences 66, 1858-1867, 2009 | 400 | 2009 |
| Protein kinase CK2–a key suppressor of apoptosis KA Ahmad, G Wang, G Unger, J Slaton, K Ahmed Advances in enzyme regulation 48 (1), 179-187, 2008 | 298 | 2008 |
| Emergence of protein kinase CK2 as a key target in cancer therapy JH Trembley, Z Chen, G Unger, J Slaton, BT Kren, C Van Waes, K Ahmed Biofactors 36 (3), 187-195, 2010 | 228 | 2010 |
| Targeting CK2 for cancer therapy KA Ahmad, G Wang, J Slaton, G Unger, K Ahmed Anti-cancer drugs 16 (10), 1037-1043, 2005 | 172 | 2005 |
| Protein kinase CK2 as regulator of cell survival: implications for cancer therapy GM Unger, AT Davis, JW Slaton, K Ahmed Current cancer drug targets 4 (1), 77-84, 2004 | 162 | 2004 |
| Downregulation of CK2 induces apoptosis in cancer cells–a potential approach to cancer therapy G Wang, G Unger, KA Ahmad, JW Slaton, K Ahmed Molecular and cellular biochemistry 274, 77-84, 2005 | 148 | 2005 |
| Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model JW Slaton, GM Unger, DT Sloper, AT Davis, K Ahmed Molecular Cancer Research 2 (12), 712-721, 2004 | 147 | 2004 |
| Nanoparticle encapsulation system and method GM Unger US Patent 6,632,671, 2003 | 145 | 2003 |
| Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice BT Kren, GM Unger, L Sjeklocha, AA Trossen, V Korman, ... The Journal of clinical investigation 119 (7), 2086-2099, 2009 | 132 | 2009 |
| CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub–50-nm … MS Brown, OT Diallo, M Hu, R Ehsanian, X Yang, P Arun, H Lu, V Korman, ... Clinical Cancer Research 16 (8), 2295-2307, 2010 | 108 | 2010 |
| A Wound-Induced [Ca2+] iIncrease and Its Transcriptional Activation of Immediate Early Genes Is Important in the Regulation of Motility POT Tran, LE Hinman, GM Unger, PJ Sammak Experimental cell research 246 (2), 319-326, 1999 | 97 | 1999 |
| Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy BT Kren, GM Unger, MJ Abedin, RI Vogel, CM Henzler, K Ahmed, ... Breast cancer research 17, 1-21, 2015 | 83 | 2015 |
| Improving surgical wound healing with basic fibroblast growth factor after radiation DB Hom, GM Unger, KJ Pernell, JC Manivel The Laryngoscope 115 (3), 412-422, 2005 | 73 | 2005 |
| Nanoparticle delivery systems and methods of use thereof G Unger, B Lundell US Patent App. 10/410,659, 2004 | 61 | 2004 |
| CK2 signaling in androgen‐dependent and‐independent prostate cancer G Wang, KA Ahmad, G Unger, JW Slaton, K Ahmed Journal of cellular biochemistry 99 (2), 382-391, 2006 | 49 | 2006 |
| Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice JH Trembley, GM Unger, DK Tobolt, VL Korman, G Wang, KA Ahmad, ... Molecular and cellular biochemistry 356, 21-35, 2011 | 44 | 2011 |
| Biologic modulations with nanoparticles C John, G Unger US Patent App. 10/409,786, 2004 | 42 | 2004 |
| Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells JH Trembley, GM Unger, VL Korman, DK Tobolt, Z Kazimierczuk, ... Cancer letters 315 (1), 48-58, 2012 | 40 | 2012 |
| Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma GM Unger, BT Kren, VL Korman, TG Kimbrough, RI Vogel, FG Ondrey, ... Molecular cancer therapeutics 13 (8), 2018-2029, 2014 | 32 | 2014 |
| Nanocapsule encapsulation system and method G Unger US Patent App. 10/652,814, 2004 | 31 | 2004 |
